Protagonist Therapeutics Inc Share Price

NASDAQ: PTGX

Mid Cap

$62.14

+2.92

(+4.93%)

as on September 19, 2025 at 1:29 am IST

$₹

Protagonist Therapeutics Inc Stock Performance

as on September 19, 2025 at 1:29 am IST

Day's Low
Day's High
$58.91
Day's Price Range
$62.18
$62.14
5.20%
Downside
0.06%
Upside
52 Week's Low
52 Week's High
$33.31
52-Week Price Range
$61.89
$62.14
46.40%
Downside
-0.40%
Upside

Protagonist Therapeutics Inc share price movements today

Previous Close: $59.22
Open: $59.55
Volume: 1.4M
Day's Low - High: $58.91 - $62.18
52 Week Low - High: $33.31 - $61.89

Protagonist Therapeutics Inc Historical Returns

1 Month Return: + 5.35 %
3 Month Return: + 9.83 %
1 Year Return: + 32.28 %
3 Year Return: + 608.37 %
5 Year Return: + 169.18 %

Protagonist Therapeutics Inc Stock Fundamentals & Key Indicators

Check Protagonist Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.6B

EPS (TTM)

-1.9783

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

3.51%

PE Ratio (TTM)

80.26

Industry PE ratio

10.127857142857144

P/B Ratio

80.2603

PEG Ratio

0

EBITDA

24.9M

Revenue (TTM)

209.2M

Profit Margin

24.88%

Return On Equity TTM

8.61%

Protagonist Therapeutics Inc Stock Valuation

Track how Protagonist Therapeutics Inc P/E has moved over time to understand its valuation trends.

Protagonist Therapeutics Inc in the last 5 years

Overview
Trends

Lowest (10.38x)

December 31, 2024

Industry (10.13x)

September 18, 2025

Today (80.26x)

September 18, 2025

Highest (68.56x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 80.26x

Protagonist Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Protagonist Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Protagonist Therapeutics Inc	BUY	$3.6B	169.18%	80.26	24.88%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	241.54%	-505.15	-12.96%
Vertex Pharmaceuticals Incorporated	BUY	$99.3B	45.88%	27.56	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$60.9B	5.45%	14.49	31.37%

Stock Returns calculator for Protagonist Therapeutics Inc Stock including INR - Dollar returns

The Protagonist Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

1Y
3Y
5Y
7Y

Protagonist Therapeutics Inc investment value today

Current value as on today

₹1,43,752

Returns

₹43,752

(+43.75%)

Returns from Protagonist Therapeutics Inc Stock

₹38,798 (+38.8%)

Dollar Returns*

₹4,953 (+4.95%)

Analyst Recommendation on Protagonist Therapeutics Inc Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Protagonist Therapeutics Inc. Average target price of $70.15

Protagonist Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Protagonist Therapeutics Inc.

What analysts predicted

11.42%UPSIDE

Target Price

$70.15

Current Price

$62.14

Analyzed by

12 Analysts

Target

$70.15

Protagonist Therapeutics Inc target price $70.15, a slight upside of 11.42% compared to current price of $62.14. According to 12 analysts rating.

Protagonist Therapeutics Inc Stock's Interest Amongst Investors

Search interest for Protagonist Therapeutics Inc Stock has decreased by -35% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 20, 2025 to September 19, 2025

Change:-35% versus previous 30 day period

Protagonist Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	60	254	4	4	170	28	5
Gross Profit	0	0	0	59	254	3	4	170	28	-
Operating Income	-36	-42	-38	23	206	-38	-41	126	-19	-42
EBITDA	-35	-42	-38	23	207	-38	-40	127	-19	-42
Interest Expense	2	-	-	2	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	1
Income Before Tax	-33	-38	-34	27	210	-31	-33	133	-11	-34
Income Tax Expense	-2	-3	0	-4	3	0	0	1	-	0
Net Income	-31	-38	-34	27	207	-30	-33	131	-11	-34
Net Profit Margin	0.00%	0.00%	0.00%	45.56%	81.32%	-734.73%	-710.37%	77.17%	-41.15%	-626.96%

Protagonist Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	20	30	0	28	27	26	60	434
Gross Profit	0	0	20	30	0	28	24	26	60	431
Operating Income	-14	-32	-37	-42	-80	-64	-125	-131	-93	252
EBITDA	-14	-32	-37	-41	-78	-63	-123	-128	-90	252
Interest Expense	-	-	-	-	0	0	2	3	-	-
Depreciation	-	-	0	0	2	2	2	3	3	2
Income Before Tax	-14	-37	-36	-39	-77	-64	-125	-127	-78	279
Income Tax Expense	0	4	0	0	0	1	-2	-3	-14	4
Net Income	-14	-37	-36	-38	-77	-66	-122	-123	-78	275
Net Profit Margin	0.00%	0.00%	-184.20%	-125.87%	-33414.29%	-231.07%	-448.25%	-464.29%	-131.59%	63.34%

Protagonist Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-38	-34	27	207	-30	-33	131	-11	-34
Operating Cash Flow	-26	-26	16	-27	268	-27	-29	125	-28
Investing Cash Flow	25	-13	-61	6	-88	-208	-8	-94	54
Financing Cash Flow	108	35	0	7	2	12	4	11	2
Change in Cash	107	-4	-43	-14	183	-224	-33	42	28

Protagonist Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-37	-36	-38	-77	-66	-125	-127	-78	275
Operating Cash Flow	-29	3	-49	-41	-72	-107	-108	-70	184
Investing Cash Flow	-59	15	2	-53	-90	-15	91	-39	-299
Financing Cash Flow	106	65	24	46	247	129	18	170	25
Change in Cash	17	85	-23	-49	84	6	2	60	-89

Global Institutional Holdings in Protagonist Therapeutics Inc

Funds	Holdings
BlackRock Inc	15.65%
Farallon Capital Management, L.L.C.	9.82%
RTW INVESTMENTS, LLC	9.19%
Vanguard Group Inc	6.88%
Deep Track Capital, LP	4.82%

See all

Insights on Protagonist Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 3 years, PTGX stock has moved up by 638.4%
POSITIVE IMPACT
Best in 3 Years
In the last 3 years, PTGX has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 67.3% return, outperforming this stock by 38.3%

About Protagonist Therapeutics Inc

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist

Organisation	Protagonist Therapeutics Inc
Headquarters	7707 Gateway Boulevard, Newark, CA, United States, 94560
Industry	Health Technology
CEO	Dr. Dinesh V. Patel Ph.D.
E-voting on shares	Click here to vote

Key Management of Protagonist Therapeutics Inc

Name	Title
Dr. Newman Yeilding	Executive VP, Chief Scientific Officer
Mr. Carter J. King	Executive Vice President of Business Development
Dr. Samuel R. Saks M.D.	Clinical Development Advisor
Mr. Mohammad Masjedizadeh Ph.D.	Executive VP & CTO
Dr. Ashok Bhandari Ph.D.	EVP & Chief Discovery Officer
Ms. Abha Bommireddi	Executive VP & Chief of Staff
Dr. Dinesh V. Patel Ph.D.	CEO, President, Secretary & Director
Mr. Asif Ali	Executive VP & CFO
Dr. Suneel K. Gupta Ph.D.	Executive Vice President of Clinical Development
Dr. Arturo M. Molina FACP, M.D., M.S.	Chief Medical Officer

FAQs

What is Protagonist Therapeutics Inc share price today?

Protagonist Therapeutics Inc share price today is $62.14 as on September 19, 2025 at 1:29 am IST at the close of the market. Protagonist Therapeutics Inc share today touched a day high of $62.18 and a low of $58.91.

What is the 52 week high and 52 week low for Protagonist Therapeutics Inc share?

Protagonist Therapeutics Inc share touched a 52 week high of $61.89 on August 28, 2025 and a 52 week low of $33.31 on November 19, 2024. Protagonist Therapeutics Inc stock price today i.e. September 19, 2025 at 1:29 am IST is closed at $62.14,which is -0.40% down from its 52 week high and 86.55% up from its 52 week low.

What is Protagonist Therapeutics Inc's market capitalisation today?

Protagonist Therapeutics Inc market capitalisation is $0.00T as on September 19, 2025 at 1:29 am IST.

How to invest in Protagonist Therapeutics Inc Stock (PTGX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Protagonist Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Protagonist Therapeutics Inc Shares that will get you 0.0241 shares as per Protagonist Therapeutics Inc share price of $62.14 per share as on September 19, 2025 at 1:29 am IST.

What is the minimum amount required to buy Protagonist Therapeutics Inc Stock (PTGX) from India?

Indian investors can start investing in Protagonist Therapeutics Inc (PTGX) shares with as little as ₹88.114 or $1 (as of September 19, 2025 at 11:41 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Protagonist Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 19, 2025 at 11:41 am IST). Based on Protagonist Therapeutics Inc share’s latest price of $62.14 as on September 19, 2025 at 1:29 am IST, you will get 0.1609 shares of Protagonist Therapeutics Inc. Learn more about fractional shares .

What are the returns that Protagonist Therapeutics Inc has given to Indian investors in the last 5 years?

Protagonist Therapeutics Inc stock has given 169.18% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?